Advertisement

Topics

Alnylam Pharmaceuticals Company Profile

07:44 EST 23rd November 2017 | BioPortfolio

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product platform to develop a deep pipeline of drug products to treat a wide array of important diseases.
Founded by leading scientists who pioneered the discovery of RNAi, Alnylam is developing technology with the potential to specifically and potently silence disease-causing genes. RNA interference is a natural cellular process for selectively turning off the activity of genes by targeting RNA, the key intermediate between DNA and proteins. By harnessing this natural process, Alnylam is developing novel therapeutics that will utilize the natural RNAi mechanism to selectively suppress genes that produce proteins that play harmful roles in disease.

Alnylam is uniquely positioned to leverage the full potential of RNAi for therapeutic applications. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals of Cambridge, Massachusetts, and Alnylam Europe of Kulmbach, Germany. The company's leading position in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how relating to RNAi. These patents and patent applications broadly cover compositions, methods and uses of small interfering RNAs or siRNAs, the molecules that mediate RNAi. Alnylam's IP estate has been leveraged today with licenses to numerous companies for therapeutic and research market applications. Alnylam has assembled an experienced management team, strong financial resources, and world class collaborators to build a pipeline of RNAi therapeutics using both Direct RNAiTM and Systemic RNAiTM approaches. Alnylam has formed major alliances with Merck, Medtronic and Novartis.

Location

300 Third Street, 3rd Floor
Cambridge
2142
United States of America

Contact

Phone: 617-551-8200
Fax: 617-551-8101


News Articles [654 Associated News Articles listed on BioPortfolio]

Alnylam Pharmaceuticals Posting Steep Loss After Suspending Fitusiran Dosing

WASHINGTON (dpa-AFX) - Shares of Alnylam Pharmaceuticals (ALNY) have moved sharply lower during trading on Thursday, slumping by 13.6 percent. Earlier in the session, Alnylam hit its lowest intrad...

Was kommt als nächstes für Alnylam Pharmaceuticals?

Die letzten 15 Jahre waren für die Aktionäre von Alnylam Pharmaceuticals (WKN:A0CBCK) nicht einfach. Die neuen Medikamente des Unternehmens basieren auf Erkenntnissen, die 2006 mit dem Nobelpreis p....

Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics

Alnylam Pharmaceuticals plans to raise $700m through a public offering of five million shares of its common stock priced at $125...Read More... The post Deals this week: Alnylam Pharmaceuticals, Myov...

Alnylam plunges on news of fatality in fitusiran study

Shares of RNAi therapeutics company Alnylam Pharmaceuticals fell 11.65% to $76.00 in pre-market trading,…

Alnylam EVP of R&D looks forward to RNAi revolution as first approval appears imminent

Boosted by his firm’s positive Phase III presentation at last week’s ATTR meeting, Alnylam Pharmaceuticals’…

Alnylam shares reach historic high after breakthrough for RNAi therapeutics

Massachusetts, USA-based Alnylam Pharmaceuticals is presenting detailed data from its Phase III APOLLO…

Alnylam Pharmaceuticals Holding On To Substantial Gain In Afternoon Trading

WASHINGTON (dpa-AFX) - Shares of Alnylam Pharmaceuticals (ALNY) continue to see substantial strength in afternoon trading on Wednesday, with the biopharmaceutical company surging up by 48.7 percen...

Alnylam, Vir ally in deal worth potentially over $1bn

In its second agreement announced on the same day Vir Biotechnology Inc. is partnering with Alnylam Pharmaceuticals Inc. in the development of up to five RNAi therapies for infectious diseases, includ...

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [122 Associated PubMed Articles listed on BioPortfolio]

With Alnylam's amyloidosis success, RNAi approval hopes soar.

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Clinical Trials [206 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

To compare the single-dose oral bioavailability of hydrochlorothiazide 50 mg tablet of Ohm Laboratories (A subsidiary of Ranbaxy pharmaceuticals USA) with hydrochlorothiazide 50 mg tablet ...

Companies [1289 Associated Companies listed on BioPortfolio]

Alnylam Europe AG

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbru...

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery ...

Alnylam Pharmaceuticals, Inc. and The Medicines Company

Alnylam Pharmaceuticals, Inc.

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a ...

The Medicines Company and Alnylam Pharmaceuticals, Inc.

The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The C...

More Information about "Alnylam Pharmaceuticals" on BioPortfolio

We have published hundreds of Alnylam Pharmaceuticals news stories on BioPortfolio along with dozens of Alnylam Pharmaceuticals Clinical Trials and PubMed Articles about Alnylam Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnylam Pharmaceuticals Companies in our database. You can also find out about relevant Alnylam Pharmaceuticals Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record